α_1-受体阻滞剂治疗小体积前列腺增生36例  

α_1-acceptor Blocker for Treatment of Benign Prostate Hyperplasia by Relative Small Volume in 36 Cases

作　　者：吴慧敏 邓洁 王东[2] 

机构地区：[1]成都空军机关医院,四川成都610041 [2]四川省人民医院泌尿外科,四川成都610072

出　　处：《中国药业》2007年第11期38-38,共1页China Pharmaceuticals

摘　　要：目的探讨α1-受体阻滞剂(阿夫唑嗪)治疗小体积前列腺增生的意义。方法应用阿夫唑嗪3月,治疗小体积前列腺增生致膀胱流出道梗阻(BOO)患者36例(治疗组),同类患者25例给予安慰剂治疗(对照组),以国际前列腺症状评分(IPSS)、最大尿流率(Qmax)及残余尿量(PRV)评价疗效。结果治疗组患者IPSS由治疗前(26.4±5.8)分降至治疗后(3.2±1.5)分,Qmax由治疗前(7.8±4.5)mL/s升至治疗后(23.8±4.7)mL/s,PRV由治疗前(75±43.8)mL降至治疗后(3.2±2.6)mL;对照组治疗前后各项指标无明显变化。结论应用阿夫唑嗪治疗小体积前列腺增生致BOO效果显著,值得推广。Objective To investigate the significance of α1-acceptor blocker for the treatment of benign prostate hyperplasia （BPH） by relative small volume. Methods The efficacy of α1- acceptor blocker was evaluated by means of IPSS, Qmax and PRV. 36 patients were treated for 3 months and 25 patients given with placebo were compared. Results The mean score of IPSS of the patients treated with α1- acceptor blocker decreased from 26.4 ± 5.8 （pre - treatment） to 3.2 ± 1.5 （post - treatment）; the mean Qmax increased from （7.8 ± 4.5） mL/s （pre - treatment） to （23.8±4.7） mL/s （post-treatment）; and the mean score of PRV of the patients decreased from （75±43.8）mL （pre-treatment） to （3.2 ±2.6）mL （post-treatment）（P〈 0. 001）. The three indexes had no difference in the patients with placebo. Conclusion α1-acceptor blocker proves to be better for the management of the patients with bladder outlet obstruction （BOO） caused by BPH of relative small volume.

关 键 词：Α1-受体阻滞剂 前列腺增生 膀胱流出道梗阻 

分 类 号：R969.4[医药卫生—药理学] R983[医药卫生—药学]